BioSpace News Archive

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced pre-clinical data detailing research led by Kirsty J. Dixon of the Department of Surgery, Virginia Commonwealth University (VCU), and Elliott Mufson, Barrow Neurological Institute.

Lisata Therapeutics, Inc. announces its participation in the upcoming Sequire Investor Summit to be held April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) announced today the first ever data demonstrating the utility of Actimab-A to depleted myeloid derived suppressor cells (MDSCs), which are ubiquitously present within the solid tumor microenvironment as well as blood cancers.

Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation in the biopharmaceutical industry.

Mirion Technologies, Inc. (NYSE: MIR) (“Mirion”) (“Company”) announced today that it will release its financial results for the first quarter of 2023 on Wednesday, May 3, 2023.

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023.

Replicate Bioscience shared new preclinical data underscoring the strength of Replicate’s srRNA platform and its potential for oncology applications at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented data on WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida from April 14 – 19, 2023.

ANGLE plc is delighted to announce it has signed an agreement with BioView Ltd. to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer utilising ANGLE’s FDA cleared Parsortix® PC1 Clinical System to harvest CTCs and BioView’s automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs.

Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated April 14, 2022, indicating that Biophytis has regained compliance with he Nasdaq Global Select Market minimum bid price requirement.